https://www.selleckchem.com/pr....oducts/1-4-diaminobu
These factors should be considered along with the patient's preferences and individual treatment goals.The past decade has seen substantial improvements in outcomes among patients with metastatic colorectal cancer treated with first and second lines of therapy. An increasing number of patients are beginning third-line treatment and beyond. Patients have several options for third-line treatment. Several of these therapies are reserved for small subsets of patients with defined molecular characteristics, whereas
Мне нравится
Комментарий
Перепост
